In new guidelines, Heron Therapeutics Inc (NASDAQ:HRTX) has announced that Sustol will be included as an extended-release injection. A recommendation of category 1 has already been given to Sustol by the NCCN – National Comprehensive Cancer Network. Sustol is used in preventing CINV – vomiting and nausea that is caused by chemotherapy in patients who have received MEC or HEC regimens.
“(N)ovel agents that can prevent or reduce the severity of this debilitating chemotherapy side effect have the potential to not only improve the quality of life of patients, but also enable patients to complete potentially life-saving treatment,” Heron Therapeutics Inc (NASDAQ:HRTX)’s Chief Executive Officer, Barry Quart, said.
Evidence And Consensus
As an alliance that is not geared towards profit, the guidelines issued by NCCN are based on evidence and are passed after reaching consensus. They are aimed at assisting patients to get services that will ensure the best possible outcome.
The Food and Drug Administration of the United States gave approval for Sustol last year in August and the drug is meant to be used as a combo therapy by being paired with antiemetics. This is mainly in adults and it is to prevent vomiting and nausea in patients undergoing chemotherapy. With regards to Heron Therapeutics Inc (NASDAQ:HRTX)’s technology of drug delivery that is polymer-based, Sustol is the first therapy to get approval.
Not Recommended For All Adults
Sustol is, however, not suitable for patients who are hypersensitive to granisetron. Patients who are also hypersensitive to any or all of Sustol’s components are also advised against using the treatment. Sustol is also not recommended for patients with a hypersensitivity to any 5-HT3 receptor. The treatment should also be avoided in patients who are suffering from serious renal impairment. Patients suffering from a renal impairment that is not severe can, however, take the drug.
Since Sustol is injected into the body, sometimes reactions at the site of injection may occur. This includes induration, swelling, nodules, tenderness, pain, bleeding or infection. In some cases, these site reactions could happen even after a fortnight following the administration of Sustol.
In Tuesday’s trading session, shares of Heron Therapeutics Inc (NASDAQ:HRTX) fell by 5.61% to close the day at $14.30.
Note: This article is written by Adam Russell and originally published at Market Exclusive.